Research
Two Biologics for Psoriatic Arthritis Square Off in Big Trial
The Brief
- A large head-to-head trial compared bimekizumab (Bimzelx) with risankizumab (Skyrizi) as treatments for psoriatic arthritis.
- The trial was reported at a meeting in Orlando and identified a winner, though with some caveats.
Why it matters
Head-to-head comparisons of biologic treatments give clinicians direct evidence for choosing between options for psoriatic arthritis.
Who’s affected
- rheumatologists and dermatologists treating psoriatic arthritis
- patients with psoriatic arthritis considering biologic therapy
- #psoriatic arthritis
- #bimekizumab
- #risankizumab
- #head-to-head trial
- #biologics
- #rheumatology
(MedPage Today) -- ORLANDO -- A large head-to-head trial reported here that pitted bimekizumab (Bimzelx) against risankizumab (Skyrizi) as treatment for psoriatic arthritis (PsA) yielded a winner, albeit with a couple caveats. Arthritic symptoms...
Timeline
Head-to-head trial of bimekizumab and risankizumab in psoriatic arthritis reported at the ACR meeting in Orlando
MedPageToday.com - medical news for physicians
Two Biologics for Psoriatic Arthritis Square Off in Big Trial